Thrombocytosis in solid tumors. Trombocitosis en tumores sólidos.

Abstract

Introduction: Platelets play a role in invasion and cancer. Thrombocytosis has been used as a paraneoplastic marker of inflammation and prognosis in solid tumors. Objective: To determine the relationship between thrombocytosis (>450 thousand cel/μl) with the clinical stage, metastasis and histopathology in patients with solid tumors. Methods: Analytical cross-sectional study, including 170 medical records, of patients not exposed to chemotherapy at diagnosis with solid tumors, describing clinical characteristics and the association of thrombocytosis with clinical stage, histological type, degree of differentiation, molecular profile and metastasis. The analyzes were performed with logistic regression, Stata version 12.0. Results: 76% female, median 63 years, median platelets of 249.000 cel/µl. breast cancer in 61.1%, prostate 12.3%, colon 15.8%, lung 5.88% and ovary 4.7%. Presence of metastasis in 37%, 23.5% with visceral metastasis, 13.5% with bone metastasis, and 4% of all patients with visceral and bone metastases. Thrombocytosis was associated with the presence of metastasis OR: 6.66 (CI: 1.29-34) p = 0.023; among the metastases, thrombocytosis was associated with visceral involvement OR: 6 (CI 1.36-26.3) p=0.018. There was no association of thrombocytosis with histological type, molecular profile in breast cancer, Gleason score in prostate cancer, or with bone metastases. Conclusions: The high value of platelets was associated in this study with the presence of visceral metastatic disease. It is necessary to expand the sample in order to confirm these results and perform studies that relate to therapeutic efficacy